{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T13:41:35Z","timestamp":1766497295423,"version":"3.48.0"},"reference-count":137,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Considerable global cancer burden is attributable to infectious agents, or oncomicrobes, which provides an opportunity to limit cancer by vaccination. Hepatitis B virus and human papillomavirus vaccines exemplify this strategy, by significantly reducing cases of liver and cervical cancer, respectively, and highlight the potential of extending this approach to other oncomicrobial targets. However, to date, effective vaccines against other well-established oncomicrobes have not been developed, and novel oncomicrobes continue to emerge. In this review, we provide an overview of vaccination and vaccine design, with an emphasis on the key factors (vaccine type, antigen selection, administration route, and vaccination timing) to consider when developing oncomicrobial vaccines, and we summarize the current state and future directions of vaccination for several established and emerging oncomicrobes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015610","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:54:17Z","timestamp":1759323257000},"page":"6469-6480","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Applying principles of vaccine development to oncomicrobial vaccines"],"prefix":"10.1182","volume":"9","author":[{"given":"Cody A.","family":"Despins","sequence":"first","affiliation":[{"name":"1Department of Basic and Translational Research; BC Cancer Research Institute, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J. P.","family":"Viegas","sequence":"additional","affiliation":[{"name":"1Department of Basic and Translational Research; BC Cancer Research Institute, Vancouver, BC, Canada"},{"name":"2Department of Medical Genetics, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7259-1247","authenticated-orcid":false,"given":"Robert A.","family":"Holt","sequence":"additional","affiliation":[{"name":"1Department of Basic and Translational Research; BC Cancer Research Institute, Vancouver, BC, Canada"},{"name":"2Department of Medical Genetics, The University of British Columbia, Vancouver, BC, Canada"},{"name":"3Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"suppl 1","key":"2025122308311414900_bib1","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.vaccine.2023.07.033","article-title":"Modeling the impact of vaccination for the immunization Agenda 2030: deaths averted due to vaccination against 14 pathogens in 194 countries from 2021 to 2030","volume":"42","author":"Carter","year":"2024","journal-title":"Vaccine"},{"issue":"4","key":"2025122308311414900_bib2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1084\/jem.13.4.397","article-title":"A sarcoma of the fowl transmissible by an agent separable from the tumor cells","volume":"13","author":"Rous","year":"1911","journal-title":"J Exp Med"},{"issue":"4","key":"2025122308311414900_bib3","doi-asserted-by":"crossref","first-page":"e20201754","DOI":"10.1084\/jem.20201754","article-title":"The road from Rous sarcoma virus to precision medicine","volume":"218","author":"Elemento","year":"2021","journal-title":"J Exp Med"},{"issue":"2","key":"2025122308311414900_bib4","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis","volume":"8","author":"de Martel","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"1","key":"2025122308311414900_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.chom.2022.10.016","article-title":"Prospects for preventing cancer with anti-microbial prophylactic vaccines","volume":"31","author":"Schiller","year":"2023","journal-title":"Cell Host Microbe"},{"issue":"4","key":"2025122308311414900_bib6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens--part B: biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol"},{"issue":"7","key":"2025122308311414900_bib7","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/cid\/cir007","article-title":"\u201cHerd immunity\u201d: a rough guide","volume":"52","author":"Fine","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2025122308311414900_bib8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1023\/A:1007626510002","article-title":"Herd immunity and herd effect: new insights and definitions","volume":"16","author":"John","year":"2000","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"2025122308311414900_bib9","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jaci.2006.09.037","article-title":"Smallpox vaccines: past, present, and future","volume":"118","author":"Parrino","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2025122308311414900_bib10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/vaccines3020320","article-title":"Vaccine adjuvants: from 1920 to 2015 and beyond","volume":"3","author":"Di Pasquale","year":"2015","journal-title":"Vaccines (Basel)"},{"issue":"34","key":"2025122308311414900_bib11","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.1073\/pnas.1400472111","article-title":"History of vaccination","volume":"111","author":"Plotkin","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"2025122308311414900_bib12","doi-asserted-by":"crossref","first-page":"12420","DOI":"10.1073\/pnas.1635213100","article-title":"The primary mechanism of attenuation of bacillus Calmette-Gu\u00e9rin is a loss of secreted lytic function required for invasion of lung interstitial tissue","volume":"100","author":"Hsu","year":"2003","journal-title":"PNAS"},{"issue":"2","key":"2025122308311414900_bib13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"10230","key":"2025122308311414900_bib14","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(20)30213-0","article-title":"The case for replacing live oral polio vaccine with inactivated vaccine in the Americas","volume":"395","author":"Alfaro-Murillo","year":"2020","journal-title":"The Lancet"},{"edition":"10th ed","year":"2022","author":"Murphy","key":"2025122308311414900_bib15"},{"issue":"6","key":"2025122308311414900_bib16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"32 pt A","key":"2025122308311414900_bib17","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/j.vaccine.2017.12.079","article-title":"Explanations for the high potency of HPV prophylactic vaccines","volume":"36","author":"Schiller","year":"2018","journal-title":"Vaccine"},{"key":"2025122308311414900_bib18","doi-asserted-by":"crossref","first-page":"102210","DOI":"10.1016\/j.coi.2022.102210","article-title":"Viral vector vaccines","volume":"77","author":"McCann","year":"2022","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"2025122308311414900_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41541-022-00503-y","article-title":"The use of viral vectors in vaccine development","volume":"7","author":"Travieso","year":"2022","journal-title":"NPJ Vaccin"},{"issue":"9","key":"2025122308311414900_bib20","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J Clin Invest"},{"issue":"11","key":"2025122308311414900_bib21","doi-asserted-by":"crossref","first-page":"e2307800120","DOI":"10.1073\/pnas.2307800120","article-title":"Endosomal escape: a bottleneck for LNP-mediated therapeutics","volume":"121","author":"Chatterjee","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2025122308311414900_bib22","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","article-title":"The 60-year evolution of lipid nanoparticles for nucleic acid delivery","volume":"23","author":"Cullis","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2025122308311414900_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2217\/fvl-2021-0170","article-title":"A brief review on DNA vaccines in the era of COVID-19","volume":"17","author":"Shafaati","year":"2021","journal-title":"Future Virol"},{"key":"2025122308311414900_bib24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.copbio.2021.09.016","article-title":"Principles for designing an optimal mRNA lipid nanoparticle vaccine","volume":"73","author":"Kon","year":"2022","journal-title":"Curr Opin Biotechnol"},{"issue":"21","key":"2025122308311414900_bib25","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Karik\u00f3","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"2025122308311414900_bib26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines-a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2025122308311414900_bib27","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.omtn.2023.05.004","article-title":"The impact of nucleoside base modification in mRNA vaccine is influenced by the chemistry of its lipid nanoparticle delivery system","volume":"32","author":"Bernard","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"2025122308311414900_bib28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-023-01408-5","article-title":"Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2025122308311414900_bib29","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s42003-023-04555-1","article-title":"Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals","volume":"6","author":"Connors","year":"2023","journal-title":"Commun Biol"},{"issue":"3","key":"2025122308311414900_bib30","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1073\/pnas.1916131117","article-title":"Host protein glycosylation in nucleic acid vaccines as a potential hurdle in vaccine design for nonviral pathogens","volume":"117","author":"Ozdilek","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025122308311414900_bib31","doi-asserted-by":"crossref","first-page":"102348","DOI":"10.1016\/j.sbi.2022.102348","article-title":"Glycosylation as a key parameter in the design of nucleic acid vaccines","volume":"73","author":"Ozdilek","year":"2022","journal-title":"Curr Opin Struct Biol"},{"issue":"20","key":"2025122308311414900_bib32","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 \u2014 preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"2025122308311414900_bib33","first-page":"101","article-title":"Update on safety and efficacy of HPV vaccines: focus on Gardasil","volume":"10","author":"Soliman","year":"2021","journal-title":"Int J Mol Cell Med"},{"key":"2025122308311414900_bib34","unstructured":"CDC\n          . Selecting Viruses for the Seasonal Influenza Vaccine. Accessed 10 October 2025. https:\/\/www.cdc.gov\/flu\/vaccine-process\/vaccine-selection.html."},{"issue":"1","key":"2025122308311414900_bib35","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/14760584.2023.2245890","article-title":"Sporozoite immunization: innovative translational science to support the fight against malaria","volume":"22","author":"Richie","year":"2023","journal-title":"Expert Rev Vaccin"},{"issue":"3","key":"2025122308311414900_bib36","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1128\/iai.64.3.905-912.1996","article-title":"Surface localization of Helicobacter pylori urease and a heat shock protein homolog requires bacterial autolysis","volume":"64","author":"Phadnis","year":"1996","journal-title":"Infect Immun"},{"issue":"1","key":"2025122308311414900_bib37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00006454-200101000-00013","article-title":"Immunologic correlates of protection induced by vaccination","volume":"20","author":"Plotkin","year":"2001","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"2025122308311414900_bib38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/589862","article-title":"Correlates of vaccine-induced immunity","volume":"47","author":"Plotkin","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2025122308311414900_bib39","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccin Immunol"},{"issue":"3","key":"2025122308311414900_bib40","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.immuni.2020.08.001","article-title":"Multifaceted effects of antigen valency on B cell response composition and differentiation in vivo","volume":"53","author":"Kato","year":"2020","journal-title":"Immunity"},{"issue":"5","key":"2025122308311414900_bib41","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3390\/vaccines9050431","article-title":"A nanoscaffolded spike-RBD vaccine provides protection against SARS-CoV-2 with minimal anti-scaffold response","volume":"9","author":"Lain\u0161\u010dek","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"2025122308311414900_bib42","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1038\/s41467-023-38457-x","article-title":"saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern","volume":"14","author":"Komori","year":"2023","journal-title":"Nat Commun"},{"key":"2025122308311414900_bib43","doi-asserted-by":"crossref","first-page":"595297","DOI":"10.3389\/fimmu.2020.595297","article-title":"Understanding early-life adaptive immunity to guide interventions for pediatric health","volume":"11","author":"Semmes","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"2025122308311414900_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41385-021-00428-0","article-title":"Mucosal immunity to poliovirus","volume":"15","author":"Connor","year":"2022","journal-title":"Mucosal Immunol"},{"issue":"4","key":"2025122308311414900_bib45","doi-asserted-by":"crossref","first-page":"e1002599","DOI":"10.1371\/journal.ppat.1002599","article-title":"Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge","volume":"8","author":"Hird","year":"2012","journal-title":"Plos Pathog"},{"key":"2025122308311414900_bib46","first-page":"334","article-title":"Live attenuated malaria vaccine designed to protect through hepatic CD8 + T cell immunity","volume":"2011","author":"Epstein","year":"1979","journal-title":"Science"},{"issue":"14","key":"2025122308311414900_bib47","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"key":"2025122308311414900_bib48","doi-asserted-by":"crossref","first-page":"215652","DOI":"10.1016\/j.canlet.2022.215652","article-title":"Long term outcome of prevention of liver cancer by hepatitis B vaccine: results from an RCT with 37 years","volume":"536","author":"Cao","year":"2022","journal-title":"Cancer Lett"},{"issue":"1","key":"2025122308311414900_bib49","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/bjc.2011.215","article-title":"Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis","volume":"105","author":"Camargo","year":"2011","journal-title":"Br J Cancer"},{"key":"2025122308311414900_bib50","doi-asserted-by":"crossref","first-page":"1525609","DOI":"10.3389\/fcimb.2025.1525609","article-title":"Prevalence of enterotoxigenic Bacteroides fragilis in patients with colorectal cancer: a systematic review and meta-analysis","volume":"15","author":"Xia","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"key":"2025122308311414900_bib51","doi-asserted-by":"crossref","first-page":"122462","DOI":"10.1016\/j.lfs.2024.122462","article-title":"Prevalence and implications of pKs-positive Escherichia coli in colorectal cancer","volume":"341","author":"de Souza","year":"2024","journal-title":"Life Sci"},{"issue":"1","key":"2025122308311414900_bib52","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13643-020-01526-z","article-title":"Detection of Fusobaterium nucleatum in feces and colorectal mucosa as a risk factor for colorectal cancer: a systematic review and meta-analysis","volume":"9","author":"Janati","year":"2020","journal-title":"Syst Rev"},{"issue":"1","key":"2025122308311414900_bib53","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1038\/s41467-020-16967-2","article-title":"Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression","volume":"11","author":"Parhi","year":"2020","journal-title":"Nat Commun"},{"issue":"22","key":"2025122308311414900_bib54","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1158\/1078-0432.CCR-16-1786","article-title":"Human microbiome Fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis","volume":"22","author":"Yamamura","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"August 2019","key":"2025122308311414900_bib55","article-title":"Detection of Fusobacterium in oral and head and neck cancer samples: a systematic review and meta-analysis","volume":"112","author":"Bronzato","year":"2020","journal-title":"Arch Oral Biol"},{"issue":"6","key":"2025122308311414900_bib56","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"suppl 4","key":"2025122308311414900_bib57","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-S4-05","article-title":"The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective","volume":"15","author":"Venook","year":"2010","journal-title":"Oncologist"},{"key":"2025122308311414900_bib58","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","article-title":"Global, regional and national burden of primary liver cancer by subtype","volume":"161","author":"Rumgay","year":"2022","journal-title":"Eur J Cancer"},{"volume-title":"Hepatitis B Vaccines: WHO Position Paper \u2013 July 2017. Weekly Epidemiological Record","year":"2017","key":"2025122308311414900_bib59"},{"issue":"5","key":"2025122308311414900_bib60","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3390\/vaccines10050793","article-title":"The global impact of hepatitis B vaccination on hepatocellular carcinoma","volume":"10","author":"Flores","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"2025122308311414900_bib61","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/hep.1840010502","article-title":"A controlled clinical trial of the efficacy of the hepatitis B vaccine (heptavax B): a final report","volume":"1","author":"Szmuness","year":"1981","journal-title":"Hepatology"},{"volume-title":"Clinical Cancer Prevention. Recent Results in Cancer Research","year":"2010","author":"Chang","key":"2025122308311414900_bib62"},{"issue":"19","key":"2025122308311414900_bib63","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1001\/jama.1987.03390190075023","article-title":"A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers","volume":"257","author":"Chen","year":"1987","journal-title":"JAMA"},{"issue":"11","key":"2025122308311414900_bib64","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/OLQ.0000000000000193","article-title":"The estimated lifetime probability of acquiring human papillomavirus in the United States","volume":"41","author":"Chesson","year":"2014","journal-title":"Sex Transm Dis"},{"key":"2025122308311414900_bib65","first-page":"149","volume-title":"Human Papillomavirus: Proving and Using a Viral Cause for Cancer","author":"Moscicki","year":"2019"},{"issue":"7","key":"2025122308311414900_bib66","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jnci\/djn044","article-title":"Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections","volume":"100","author":"Rodr\u00edguez","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2025122308311414900_bib67","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Mu\u00f1oz","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"2025122308311414900_bib68","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jinf.2012.10.024","article-title":"Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer","volume":"66","author":"Chelimo","year":"2013","journal-title":"J Infect"},{"year":"2022","author":"World Health Organization","key":"2025122308311414900_bib69"},{"issue":"1","key":"2025122308311414900_bib70","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3947\/ic.2023.0064","article-title":"Comparative effects of bivalent, quadrivalent, and nonavalent human papillomavirus vaccines in the prevention of genotype-specific infection: a systematic review and network meta-analysis","volume":"56","author":"Kim","year":"2024","journal-title":"Infect Chemother"},{"issue":"19","key":"2025122308311414900_bib71","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.3748\/wjg.v12.i19.3126","article-title":"This year\u2019s Nobel Prize to gastroenterology: Robin Warren and Barry Marshall awarded for their discovery of Helicobacter pylori as pathogen in the gastrointestinal tract","volume":"12","author":"Hellstr\u00f6m","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"6","key":"2025122308311414900_bib72","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S2468-1253(23)00070-5","article-title":"Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis","volume":"8","author":"Li","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"2025122308311414900_bib73","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41572-023-00431-8","article-title":"Helicobacter pylori infection","volume":"9","author":"Malfertheiner","year":"2023","journal-title":"Nat Rev Dis Primers"},{"volume-title":"Helicobacter pylori","year":"2016","author":"Marshall","key":"2025122308311414900_bib74"},{"issue":"12","key":"2025122308311414900_bib75","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1056\/NEJMcp1710945","article-title":"Helicobacter pylori Infection","volume":"380","author":"Crowe","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"2025122308311414900_bib76","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","article-title":"Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions","volume":"155","author":"Savoldi","year":"2018","journal-title":"Gastroenterology"},{"issue":"1","key":"2025122308311414900_bib77","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1523-5378.2008.00571.x","article-title":"Helicobacter pylori recurrence in developed and developing countries: meta-analysis of 13C-urea breath test follow-up after eradication","volume":"13","author":"Niv","year":"2008","journal-title":"Helicobacter"},{"issue":"9","key":"2025122308311414900_bib78","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/apt.14319","article-title":"Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori","volume":"46","author":"Hu","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2025122308311414900_bib79","doi-asserted-by":"crossref","first-page":"1342913","DOI":"10.3389\/fcimb.2024.1342913","article-title":"Strategies of Helicobacter pylori in evading host innate and adaptive immunity: insights and prospects for therapeutic targeting","volume":"14","author":"Fan","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"issue":"12","key":"2025122308311414900_bib80","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1136\/gutjnl-2020-320839","article-title":"Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis","volume":"69","author":"Ford","year":"2020","journal-title":"Gut"},{"key":"2025122308311414900_bib81","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.2147\/IDR.S412361","article-title":"How long will it take to launch an effective Helicobacter pylori vaccine for humans?","volume":"16","author":"Li","year":"2023","journal-title":"Infect Drug Resist"},{"issue":"10002","key":"2025122308311414900_bib82","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S0140-6736(15)60310-5","article-title":"Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"Zeng","year":"2015","journal-title":"The Lancet"},{"issue":"50","key":"2025122308311414900_bib83","doi-asserted-by":"crossref","first-page":"7295","DOI":"10.1016\/j.vaccine.2018.01.001","article-title":"Status of vaccine research and development for Helicobacter pylori","volume":"37","author":"Sutton","year":"2019","journal-title":"Vaccine"},{"issue":"107","key":"2025122308311414900_bib84","doi-asserted-by":"crossref","first-page":"107fs7","DOI":"10.1126\/scitranslmed.3002878","article-title":"Epstein-Barr virus: an important vaccine target for cancer prevention","volume":"3","author":"Cohen","year":"2011","journal-title":"Sci Transl Med"},{"issue":"20","key":"2025122308311414900_bib85","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-Barr virus: biology and clinical disease","volume":"185","author":"Damania","year":"2022","journal-title":"Cell"},{"issue":"993","key":"2025122308311414900_bib86","first-page":"372","article-title":"Epstein-Barr virus and Burkitt lymphoma","volume":"84","author":"Brady","year":"2008","journal-title":"J Clin Pathol"},{"issue":"1","key":"2025122308311414900_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2014.02.005","article-title":"Progress, prospects, and problems in Epstein-Barr virus vaccine development","volume":"6","author":"Balfour","year":"2014","journal-title":"Curr Opin Virol"},{"issue":"1","key":"2025122308311414900_bib88","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41541-022-00587-6","article-title":"Urgency and necessity of Epstein-Barr virus prophylactic vaccines","volume":"7","author":"Zhong","year":"2022","journal-title":"NPJ Vaccin"},{"issue":"12","key":"2025122308311414900_bib89","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J Infect Dis"},{"key":"2025122308311414900_bib90","doi-asserted-by":"crossref","first-page":"701611","DOI":"10.3389\/fmicb.2021.701611","article-title":"Main targets of interest for the development of a prophylactic or therapeutic Epstein-Barr virus vaccine","volume":"12","author":"Jean-Pierre","year":"2021","journal-title":"Front Microbiol"},{"issue":"5","key":"2025122308311414900_bib91","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","article-title":"Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site","volume":"162","author":"Kanekiyo","year":"2015","journal-title":"Cell"},{"issue":"10455","key":"2025122308311414900_bib92","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0140-6736(24)01608-8","article-title":"Prophylactic vaccines against Epstein\u2013Barr virus","volume":"404","author":"Zhong","year":"2024","journal-title":"The Lancet"},{"issue":"34","key":"2025122308311414900_bib93","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1016\/j.vaccine.2016.06.021","article-title":"Rabbits immunized with Epstein-Barr virus gH\/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350","volume":"34","author":"Cui","year":"2016","journal-title":"Vaccine"},{"issue":"8","key":"2025122308311414900_bib94","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1469-0691.2006.01494.x","article-title":"A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer","volume":"12","author":"Ulger Toprak","year":"2006","journal-title":"Clin Microbiol Infect"},{"issue":"6375","key":"2025122308311414900_bib95","first-page":"592","article-title":"Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria","volume":"359","author":"Dejea","year":"2018","journal-title":"Science (1979)"},{"issue":"9","key":"2025122308311414900_bib96","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/nm.2015","article-title":"A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses","volume":"15","author":"Wu","year":"2009","journal-title":"Nat Med"},{"issue":"25","key":"2025122308311414900_bib97","doi-asserted-by":"crossref","first-page":"14979","DOI":"10.1073\/pnas.95.25.14979","article-title":"Bacteroides fragilis enterotoxin cleaves the zonula adherens protein, E-cadherin","volume":"95","author":"Wu","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2025122308311414900_bib98","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/gast.2003.50047","article-title":"Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation","volume":"124","author":"Wu","year":"2003","journal-title":"Gastroenterology"},{"issue":"4","key":"2025122308311414900_bib99","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1128\/iai.65.4.1431-1439.1997","article-title":"The Bacteroides fragilis toxin fragilysin disrupts the paracellular barrier of epithelial cells","volume":"65","author":"Obiso","year":"1997","journal-title":"Infect Immun"},{"issue":"4","key":"2025122308311414900_bib100","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/gut.44.4.504","article-title":"Bacteroides fragilis toxin 2 damages human colonic mucosa in vitro","volume":"44","author":"Riegler","year":"1999","journal-title":"Gut"},{"issue":"2","key":"2025122308311414900_bib101","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.chom.2018.01.007","article-title":"Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells","volume":"23","author":"Chung","year":"2018","journal-title":"Cell Host Microbe"},{"issue":"8","key":"2025122308311414900_bib102","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.1128\/IAI.73.8.5273-5277.2005","article-title":"Mutation of the zinc-binding metalloprotease motif affects Bacteroides fragilis toxin activity but does not affect propeptide processing","volume":"73","author":"Franco","year":"2005","journal-title":"Infect Immun"},{"issue":"7802","key":"2025122308311414900_bib103","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41586-020-2080-8","article-title":"Mutational signature in colorectal cancer caused by genotoxic pks + E. coli","volume":"580","author":"Pleguezuelos-Manzano","year":"2020","journal-title":"Nature"},{"issue":"2","key":"2025122308311414900_bib104","doi-asserted-by":"crossref","first-page":"e56964","DOI":"10.1371\/journal.pone.0056964","article-title":"High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer","volume":"8","author":"Buc","year":"2013","journal-title":"PLoS One"},{"issue":"5788","key":"2025122308311414900_bib105","article-title":"Escherichia coli induces DNA double-strand breaks in eukaryotic cells","volume":"313","author":"Nougayrede","year":"2006","journal-title":"Science (1979)"},{"issue":"2","key":"2025122308311414900_bib106","doi-asserted-by":"crossref","first-page":"e02393-17","DOI":"10.1128\/mBio.02393-17","article-title":"The colibactin genotoxin generates DNA interstrand cross-links in infected cells","volume":"9","author":"Bossuet-Greif","year":"2018","journal-title":"mBio"},{"issue":"25","key":"2025122308311414900_bib107","doi-asserted-by":"crossref","first-page":"11537","DOI":"10.1073\/pnas.1001261107","article-title":"Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells","volume":"107","author":"Cuevas-Ramos","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8038","key":"2025122308311414900_bib108","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41586-024-08135-z","article-title":"Colibactin-driven colon cancer requires adhesin-mediated epithelial binding","volume":"635","author":"Jans","year":"2024","journal-title":"Nature"},{"key":"2025122308311414900_bib109","first-page":"276","article-title":"Prevention of mucosal Escherichia coli infection by FimH-adhesin\u2013based systemic vaccination","volume":"1997","author":"Langermann","year":"1979","journal-title":"Science"},{"issue":"2","key":"2025122308311414900_bib110","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1086\/315258","article-title":"Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli","volume":"181","author":"Langermann","year":"2000","journal-title":"J Infect Dis"},{"issue":"7779","key":"2025122308311414900_bib111","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41586-019-1672-7","article-title":"The landscape of somatic mutation in normal colorectal epithelial cells","volume":"574","author":"Lee-Six","year":"2019","journal-title":"Nature"},{"issue":"1","key":"2025122308311414900_bib112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/vaccines9010001","article-title":"Advances in oral subunit vaccine design","volume":"9","author":"Van der Weken","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"2025122308311414900_bib113","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal vaccines \u2014 fortifying the frontiers","volume":"22","author":"Lavelle","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"8684","key":"2025122308311414900_bib114","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/0140-6736(90)90080-O","article-title":"Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up","volume":"335","author":"Clemens","year":"1990","journal-title":"The Lancet"},{"issue":"24","key":"2025122308311414900_bib115","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1161\/CIRCULATIONAHA.107.758524","article-title":"Bacteremia associated with toothbrushing and dental extraction","volume":"117","author":"Lockhart","year":"2008","journal-title":"Circulation"},{"issue":"2","key":"2025122308311414900_bib116","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1101\/gr.126516.111","article-title":"Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma","volume":"22","author":"Castellarin","year":"2012","journal-title":"Genome Res"},{"issue":"2","key":"2025122308311414900_bib117","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1101\/gr.126573.111","article-title":"Genomic analysis identifies association of Fusobacterium with colorectal carcinoma","volume":"22","author":"Kostic","year":"2012","journal-title":"Genome Res"},{"issue":"9","key":"2025122308311414900_bib118","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.18632\/oncotarget.3109","article-title":"Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis","volume":"6","author":"Mitsuhashi","year":"2015","journal-title":"Oncotarget"},{"issue":"22","key":"2025122308311414900_bib119","first-page":"23337","article-title":"Intratumoral levels and prognostic significance of Fusobacterium nucleatum in cervical carcinoma","volume":"12","author":"Huang","year":"2020","journal-title":"Aging"},{"issue":"2","key":"2025122308311414900_bib120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.chom.2016.07.006","article-title":"Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc","volume":"20","author":"Abed","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"9","key":"2025122308311414900_bib121","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/s41564-024-01784-w","article-title":"The adhesin RadD enhances Fusobacterium nucleatum tumour colonization and colorectal carcinogenesis","volume":"9","author":"Zhang","year":"2024","journal-title":"Nat Microbiol"},{"issue":"4","key":"2025122308311414900_bib122","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/j.gastro.2016.11.018","article-title":"Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating Toll-like receptor 4 signaling to nuclear factor\u2212\u03baB, and up-regulating expression of MicroRNA-21","volume":"152","author":"Yang","year":"2017","journal-title":"Gastroenterology"},{"issue":"3","key":"2025122308311414900_bib123","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.cell.2017.07.008","article-title":"Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy","volume":"170","author":"Yu","year":"2017","journal-title":"Cell"},{"issue":"5","key":"2025122308311414900_bib124","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chom.2023.04.010","article-title":"Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer","volume":"31","author":"Jiang","year":"2023","journal-title":"Cell Host Microbe"},{"issue":"45","key":"2025122308311414900_bib125","doi-asserted-by":"crossref","first-page":"e2306281","DOI":"10.1002\/adma.202306281","article-title":"Antibacterial Fusobacterium nucleatum-mimicking nanomedicine to selectively eliminate tumor-colonized bacteria and enhance immunotherapy against colorectal cancer","volume":"35","author":"Chen","year":"2023","journal-title":"Adv Mater"},{"issue":"641","key":"2025122308311414900_bib126","doi-asserted-by":"crossref","first-page":"eaba9157","DOI":"10.1126\/scisignal.aba9157","article-title":"Fusobacterium nucleatum host cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration","volume":"13","author":"Casasanta","year":"2020","journal-title":"Sci Signal"},{"issue":"10","key":"2025122308311414900_bib127","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.annonc.2020.06.003","article-title":"Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer","volume":"31","author":"Serna","year":"2020","journal-title":"Ann Oncol"},{"issue":"12","key":"2025122308311414900_bib128","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1136\/gutjnl-2015-310101","article-title":"Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis","volume":"65","author":"Mima","year":"2016","journal-title":"Gut"},{"issue":"2","key":"2025122308311414900_bib129","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1006\/anae.1999.0188","article-title":"Infinite serovar and ribotype heterogeneity among oral Fusobacterium nucleatum strains?","volume":"5","author":"Thurnheer","year":"1999","journal-title":"Anaerobe"},{"issue":"4","key":"2025122308311414900_bib130","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/gut.48.4.526","article-title":"The risk of colorectal cancer in ulcerative colitis: a meta-analysis","volume":"48","author":"Eaden","year":"2001","journal-title":"Gut"},{"issue":"suppl 10","key":"2025122308311414900_bib131","doi-asserted-by":"crossref","first-page":"K53","DOI":"10.1016\/j.vaccine.2008.06.002","article-title":"An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results","volume":"26","author":"Schiller","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"2025122308311414900_bib132","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1128\/CMR.00053-08","article-title":"Enterotoxigenic Bacteroides fragilis: a rogue among symbiotes","volume":"22","author":"Sears","year":"2009","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"2025122308311414900_bib133","first-page":"21","article-title":"Edward Jenner and the history of smallpox and vaccination","volume":"18","author":"Riedel","year":"2005","journal-title":"Proc"},{"issue":"1666","key":"2025122308311414900_bib134","doi-asserted-by":"crossref","first-page":"20140378","DOI":"10.1098\/rstb.2014.0378","article-title":"The prevention and eradication of smallpox: a commentary on Sloane (1755) \u2018An account of inoculation.\u2019","volume":"370","author":"Weiss","year":"2015","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"2","key":"2025122308311414900_bib135","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/v12020138","article-title":"Smallpox in the post-eradication Era","volume":"12","author":"Meyer","year":"2020","journal-title":"Viruses"},{"issue":"7","key":"2025122308311414900_bib136","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1258\/jrsm.2012.12k044","article-title":"The origins of inoculation","volume":"105","author":"Boylston","year":"2012","journal-title":"J R Soc Med"},{"issue":"JUN","key":"2025122308311414900_bib137","first-page":"21","article-title":"Edward Jenner and the small pox vaccine","volume":"2","author":"Smith","year":"2011","journal-title":"Front Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6469\/2475205\/blooda_adv-2024-015610-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6469\/2475205\/blooda_adv-2024-015610-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T13:31:32Z","timestamp":1766496692000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/24\/6469\/547539\/Applying-principles-of-vaccine-development-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":137,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015610","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published-other":{"date-parts":[[2025,12,23]]},"published":{"date-parts":[[2025,12,12]]}}}